Empowering Health

ODI Pharma is a pharmaceutical company specialized in medicinal cannabis.

Since 2018 - with the goal to improve patients' lives.

Based on its European network, subsidiaries and partners, ODI is a producer and representative of pharmaceutical cannabis finished products under governmental supervision and regulation with a focus on distribution to medicinal markets, initially targeting Eastern Europe. Currently, ODI has distribution contracts representing supply contracts to 14,000+ pharmacies, hundreds of specialty clinics and multiple hospitals. We strive to provide consistent high quality, medical grade pharmaceuticals that fulfill strictest market standards. Our team is dedicated and committed to support the medical industry to implement the evolution of medicinal cannabis.

News & Press Release

News

Kommuniké från årsstämma i ODI Pharma AB (publ)

Idag den 5 december 2025 hölls årsstämma i ODI Pharma AB (publ). Nedan följer en sammanfattning av de beslut som fattades. Samtliga beslut fattades med erforderlig majoritet. Fastställande av resultaträkning och balansräkning Årsstämman beslutade att fastställa den framlagda resultaträkningen och balansräkningen samt koncernresultaträkningen och koncernbalansräkningen. Dispositioner beträffande bolagets resultat enligt den fastställda balansräkningen Årsstämman beslutade at

5. Dez.2 Min. Lesezeit

Notice to Annual General Meeting in ODI Pharma AB (publ)

Today, the 5 th of December 2025, ODI Pharma AB (publ) held its Annual General Meeting ("AGM"). Below is a summary of the decisions made. All decisions were made with the required majority. Adoption of the income statement and balance sheet The AGM resolved to adopt the profit and loss account and balance sheet presented, and the consolidated income statement and consolidated balance sheet. Allocation of the company's profit or loss The AGM resolved to dispose of the compa

5. Dez.2 Min. Lesezeit

Publication of interim report Q1 2025/2026

ODI Pharma AB (“ODI” or the “Company”) hereby publishes its interim report for the period July 2025 - September 2025. The report is available as an attached document to this press release and on the Company's website ( www.odipharma.com ). Below is a summary of the report. First quarter (2025-07-01 – 2025-09-30) · The Group's net sales amounted to SEK 5,968,143 (143,793). · The Group's profit after financial items amounted to SEK -37,027 (-1,468,183). ·

27. Nov.2 Min. Lesezeit

Our Mission

It is ODI's mission to promote and make the product available to patients in need in a controlled environment to prevent any negative side effects. The cannabis plant was neglected in the pharmaceutical industry for a period too long. We support additional research to improve the safeness of usage of the product even further.

14k+

Pharmacies

Instant access to pharmacies purchasing the products

100+

Clinics

We reach most clinics, researching and prescribing medicinal cannabis in Europe

23

countries in Europe

With our distribution network we reach up to almost all countries in Europe

ODI Pharma AB - prime choice for your investment

Our Values

WHAT WE STAND FOR

Attentiveness

Expertise

Support

At ODI Pharma, we believe that there can be no value creation without the founding values that guide our action and form the basis of our corporate culture.

The ability to invest in people to improve relationship and moral standards as well as purely technical standards has proved highly positive. It is simple values, such as kindness, compassion, empathy, availability, trust and educational support, that give ODI Pharma the reputation, just as much as performance in terms of skills and expertise.

We strive to make all our products available to those who are in need in order to live a full and enjoyable life.

Our success is based on expertise. Expertise is the cornerstone of ODI Pharma. It is applied in the selection of our business partners, research partners and all our financial decisions. There are no short-cuts in a developing an industry. Thorough due diligence and project evaluation is key to succeed in our industry.

Expertise drives us to maintain and improve our status through training, research and continuing education. We share our expertise with our clients so our clients don’t have to invest in building infrastructure.

ODI Pharma is viewed as the team who leads the evolution of a regulated medicinal cannabis market in Europe.

ODI Pharma puts high emphasis on the support of the dynamic medical cannabis market, its market participants, but first and foremost our clients, patients and medical practitioners.

We are continuously supporting research projects to better understand the product and the development of new applications.

Communication is an essential quality that ODI Pharma strives to apply to its day-to-day operations.

Medicinal Cannabis

Today, medicinal cannabis is a catch-all term for anything from dried cannabis flowers, cannabis oils, capsules, tablets, oromucosal spray and so on. But common to all of these product types is that...